Phase III InPedILD trial enrolls first patient to evaluate nintedanib in pediatric population with…
Boehringer Ingelheim announced that the first patient has enrolled in InPedILD, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and…
Read More...
Read More...
